Andrew McCall, MD
Urology · Baton Rouge, LANPI 1790122299
Payments from drug & device makers
Across 232 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$966
- AbbVie$898
- Sumitomo Pharma America, Inc.$801
- Dendreon Pharmaceuticals LLC$217
- Myriad Genetic Laboratories, Inc.$200
- Johnson & Johnson$197
- plus $1K from 31 others
What the payments were for
- Food & beverage$4,30796%
- Education$1884%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 57 | $966 |
| AbbVie(2 entities) | 55 | $898 |
| Sumitomo Pharma America, Inc. | 36 | $801 |
| Dendreon Pharmaceuticals LLC | 9 | $217 |
| Myriad Genetic Laboratories, Inc. | 6 | $200 |
| Johnson & Johnson(2 entities) | 15 | $197 |
| Procept Biorobotics Corporation | 4 | $192 |
| Urogen Pharma, Inc. | 5 | $138 |
| Urovant Sciences Inc | 4 | $83 |
| Progenics Pharmaceuticals, Inc. | 2 | $70 |
| Stryker | 1 | $67 |
| Pfizer | 4 | $62 |
| Ferring Pharmaceuticals Inc. | 3 | $56 |
| Antares Pharma, Inc. | 3 | $53 |
| Tolmar Pharmaceuticals, Inc. | 3 | $52 |
| AstraZeneca | 1 | $35 |
| Endo Pharmaceuticals Inc. | 2 | $33 |
| Mission Pharmacal Company | 2 | $32 |
| Novartis | 1 | $26 |
| Bayer | 2 | $24 |
| Civco Medical Instruments | 1 | $23 |
| Blue Earth Diagnostics | 1 | $21 |
| 180 Medical, Inc. | 1 | $20 |
| Agiliti Surgical, Inc. | 1 | $20 |
| Endo USA, Inc. | 1 | $19 |
| Ambu Inc. | 1 | $19 |
| Immunitybio, Inc. | 1 | $18 |
| Intuitive Surgical | 1 | $18 |
| Neotract Inc. | 1 | $18 |
| Telix Pharmaceuticals | 1 | $17 |
| Tolmar, Inc. | 1 | $17 |
| Axonics, Inc. | 1 | $16 |
| Coloplast | 1 | $16 |
| Teleflex LLC | 1 | $15 |
| Acerus Pharmaceuticals Corporation | 1 | $14 |
| Medtronic | 1 | $12 |
| Duchesnay USA Incorporated | 1 | $11 |
How this compares
$4,495 in reported general payments places this provider in the 60th percentile of 199 urology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 212 | $167,580 |
| GemtesaVibegron | 92 | $60,940 |
| Tamsulosin Hcl | 1,039 | $12,071 |
| Doxycycline Hyclate | 96 | $11,123 |
| Silodosin | 132 | $10,412 |
| Finasteride | 577 | $7,944 |
| NitrofurantoinNitrofurantoin Macrocrystal | 167 | $6,020 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 140 | $3,800 |
| Oxybutynin Chloride ErOxybutynin Chloride | 250 | $2,565 |
| Cefdinir | 160 | $2,321 |
| Estradiol | 33 | $2,215 |
| Potassium Citrate ErPotassium Citrate | 44 | $2,166 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 93 | $2,165 |
| Desmopressin Acetate | 24 | $1,730 |
| Methenamine Hippurate | 11 | $1,727 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $966 | $167,580212 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $801 | $60,94092 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 199 urology providers in Louisiana.
Other urology in Baton Rouge
- Jason BridgesBaton Rouge$15K
- James MorrisBaton Rouge$8K
- Stephen VickBaton Rouge$7K
- Ralph HendersonShreveport$4M
- Kevin ClineShreveport$1.3M
- Nathan FischmanNew Orleans$1.3M
- Ashley BakerShreveport$705K
- Colin GoudelockeNew Orleans$615K
- Stephen BardotNew Orleans$572K
- Gerard HenryBossier City$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.